AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11535320 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine administered by one JI device
Number of subjects: 304
Study 11535320 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine administered by needle and syringe (N&S)
Number of subjects: 304
Study 9716243 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline (300 mg t.i.d. taken 1 h before meals)
Number of subjects: 1260
Study 9716243 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline
Number of subjects: 1260
Study 9716243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1260
Study 8142094 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac 30 mg loading dose followed by IV ketorolac 15 mg every 6 hours (Group 2)
Number of subjects: 62
Study 8142094 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac 60 mg loading dose followed by IV ketorolac 30 mg every 6 hours (Group 3)
Number of subjects: 62
Study 8142094 — intervention group
Group type: COMPARATOR
Intervention: IV saline (placebo) followed by IV saline every 6 hours (Group 1)
Number of subjects: 62
Study 3045341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (20 mcg)
Number of subjects: 12
Study 3045341 — intervention group
Group type: COMPARATOR
Intervention: Papaverine (7.5 mg) plus Phentolamine (0.25 mg)
Number of subjects: 12
Study 29620927 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple home visits conducted by lay health workers including health education, couple relationship and communication skills, and offers of couple HIV testing and counseling (CHTC) services.
Number of subjects: 127
Study 29620927 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 127
Study 26124656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps isokinetic endurance test at 90° per second
Number of subjects: 14
Study 26124656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps isokinetic endurance test at 180° per second
Number of subjects: 14
Study 26124656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea and leg fatigue scores at both angular velocities
Number of subjects: 14
Study 23219086 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 246
Study 21552726 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect intervention (Therapy Group - TG)
Number of subjects: 11
Study 21552726 — intervention group
Group type: COMPARATOR
Intervention: Indirect intervention only (Orientation Group - OG)
Number of subjects: 11
Study 18499632 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg clonidine with 0.375% bupivacaine
Number of subjects: 99
Study 18499632 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg clonidine IM
Number of subjects: 99
Study 18499632 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 99
Study 16542657 — intervention group
Group type: COMPARATOR
Intervention: 125 mL intravenous fluid per hour
Number of subjects: 300
Study 16542657 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL intravenous fluid per hour
Number of subjects: 300
Study 12975159 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 20
Study 12975159 — intervention group
Group type: COMPARATOR
Intervention: ALA-ME-PDT
Number of subjects: 20
Study 12975159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 10352088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 20 mg/day for 7 days (group A)
Number of subjects: 120
Study 10352088 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 2 x 40 mg/day for 7 days (group B)
Number of subjects: 120
Study 10352088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups continued treatment with omeprazole (40 mg/day days 8-14 and 20 mg/day days 15-28)
Number of subjects: 120
Study 10352088 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects recorded in group A
Number of subjects: 120
Study 10352088 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects recorded in group B
Number of subjects: 120
Study 8686945 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (6.0 million KIU)
Number of subjects: 100
Study 8686945 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 1858988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with 1:400,000 epinephrine
Number of subjects: 100
Study 1858988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:400,000 epinephrine
Number of subjects: 100
Study 1858988 — intervention group
Group type: COMPARATOR
Intervention: Control group (vasoconstrictor alone)
Number of subjects: 100
Study 1858988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 100
Study 6685039 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Loads (OL) for the legs: 5.04 Joule x Rev-1 x kg B.W.-1 for women and 5.13 Joule x Rev-1 x kg B.W.-1 for men.
Number of subjects: 35
Study 6685039 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Loads (OL) for the arms: 2.82 Joule x Rev-1 x kg B.W.-1 for women and 3.52 Joule x Rev-1 x kg B.W.-1 for men.
Number of subjects: 35
Study 6685039 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance loads ranged from 2.43 to 5.39 Joule per pedal revolution per kg body weight for legs and from 1.96 to 3.92 for arms.
Number of subjects: 35
Study 29807102 — intervention group
Group type: EXPERIMENTAL
Intervention: Subetta add-on therapy
Number of subjects: 144
Study 29807102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 27581472 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy intake at lunch (LM)
Number of subjects: 80
Study 27581472 — intervention group
Group type: COMPARATOR
Intervention: High energy intake at dinner (DM)
Number of subjects: 80
Study 25503168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg or 20 mg of melatonin
Number of subjects: 0
Study 25503168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22424024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10995
Study 22424024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10995
Study 20001186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive-eating program
Number of subjects: 61
Study 18215534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone conversation
Number of subjects: 60
Study 18215534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone use
Number of subjects: 60
Study 18215534 — intervention group
Group type: COMPARATOR
Intervention: i-pod use
Number of subjects: 60
Study 18215534 — intervention group
Group type: COMPARATOR
Intervention: No mobile device
Number of subjects: 60
Study 16404981 — intervention group
Group type: EXPERIMENTAL
Intervention: Acilact
Number of subjects: 0
Study 16404981 — intervention group
Group type: COMPARATOR
Intervention: IRS 19 vaccine
Number of subjects: 0
Study 12702496 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine (0.8 mmol.kg body wt(‐1)x h(‐1))
Number of subjects: 0
Study 12702496 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 12702496 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous amino acids
Number of subjects: 0
Study 10551433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa receptor antagonists (parenteral formulations)
Number of subjects: 1000
Study 8607684 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (20,000 kIU/kg [2.8 mg/kg])
Number of subjects: 25
Study 8607684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 25
Study 1934206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg.kg‐1 (ED95)
Number of subjects: 46
Study 1934206 — intervention group
Group type: COMPARATOR
Intervention: d-tubocurarine 0.3 mg.kg‐1 (ED90)
Number of subjects: 46
Study 7072708 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 8
Study 7072708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IPF)
Number of subjects: 8
Study 7072708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6705664 — intervention group
Group type: EXPERIMENTAL
Intervention: DKNA
Number of subjects: 219
Study 6705664 — intervention group
Group type: EXPERIMENTAL
Intervention: DKNB
Number of subjects: 219
Study 6705664 — intervention group
Group type: EXPERIMENTAL
Intervention: DKNC
Number of subjects: 219
Study 29167074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermomechanical stimulation with the Buzzy device
Number of subjects: 50
Study 29167074 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study 28116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Houpt overall behavior scale
Number of subjects: 27
Study 28116299 — intervention group
Group type: EXPERIMENTAL
Intervention: OSUBRS
Number of subjects: 27
Study 28116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Venham Behavior Rating Scale
Number of subjects: 27
Study 24641585 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week dietary intervention combined with physical exercise for weight loss
Number of subjects: 303
Study 24641585 — intervention group
Group type: COMPARATOR
Intervention: Information-only arm (simple informative counselling)
Number of subjects: 303
Study 22736737 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted self-care teaching intervention using principles of cognitive training
Number of subjects: 125
Study 22736737 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 20589733 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 15
Study 20589733 — intervention group
Group type: COMPARATOR
Intervention: Non-treated dyslipidemic T2D patients
Number of subjects: 15
Study 20589733 — intervention group
Group type: COMPARATOR
Intervention: Non-dyslipidemic T2D patients
Number of subjects: 15
Study 20589733 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 15
Study 18330955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Group 2)
Number of subjects: 76
Study 18330955 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (Group 3)
Number of subjects: 76
Study 18330955 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Group 1)
Number of subjects: 76
Study 15511602 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen preparation composed of 17-beta estradiol
Number of subjects: 0
Study 15511602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12050503 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and oxygen)
Number of subjects: 110
Study 12050503 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 110
Study 12050503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 110
Study 10480626 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP3 splice mutation (homozygous)
Number of subjects: 942
Study 8696019 — intervention group
Group type: EXPERIMENTAL
Intervention: Geliperm dressing applied to one eye
Number of subjects: 6
Study 8696019 — intervention group
Group type: COMPARATOR
Intervention: Standard eye care applied to the other eye (control)
Number of subjects: 6
Study 1761453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil, 500 mg once a day
Number of subjects: 102
Study 1761453 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor, 250 mg three times a day
Number of subjects: 102
Study 6282790 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation (TI) alone (4500‐6000 rad in 3‐6 weeks)
Number of subjects: 120
Study 6282790 — intervention group
Group type: EXPERIMENTAL
Intervention: TI (3000 rad in 2 weeks) plus cyclophosphamide, doxorubicin, vincristine (CAV)
Number of subjects: 120
Study 6282790 — intervention group
Group type: EXPERIMENTAL
Intervention: TI + CAV
Number of subjects: 120
Study 6282790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) plus high dose CAV, methotrexate and leucovorin
Number of subjects: 120
Study 30288853 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG)
Number of subjects: 150
Study 30288853 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG) in group A
Number of subjects: 150
Study 30288853 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided pulsed radiofrequency modulation targeting thoracic dorsal root ganglion (DRG) in group B
Number of subjects: 150
Study 28489320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28489320 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (COX inhibition)
Number of subjects: 24
Study 28489320 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous rewarming
Number of subjects: 24
Study 26925896 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 60
Study 26925896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23698546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 40
Study 23698546 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 19479782 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge software
Number of subjects: 631
Study 19479782 — intervention group
Group type: COMPARATOR
Intervention: Usual care, handwritten discharge
Number of subjects: 631
Study 16835147 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual pad technology A
Number of subjects: 10
Study 16835147 — intervention group
Group type: COMPARATOR
Intervention: Menstrual pad technology B
Number of subjects: 10
Study 15054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee (5 g, approximately 50 mg trigonelline)
Number of subjects: 8
Study 15054441 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 15054441 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonelline (50 mg)
Number of subjects: 8
Study 11166143 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 1668
Study 11166143 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose therapy
Number of subjects: 1668
Study 9164822 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (heavy smokers: more than 20 cigarettes/day)
Number of subjects: 57
Study 9164822 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 57
Study 9164822 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 57
Study 9164822 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 57
Study 8189732 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (actual and expected doses)
Number of subjects: 0
Study 8189732 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration
Number of subjects: 0
Study 8189732 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective intoxication
Number of subjects: 0
Study 8189732 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexperimental beliefs about the alcohol content of the beverage consumed
Number of subjects: 0
Study 2438221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (VBP regimen)
Number of subjects: 263
Study 31653225 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28034894 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml water ingestion
Number of subjects: 24
Study 28034894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-1 treatment
Number of subjects: 24
Study 28034894 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-1 and 0.8% saline cotreatment
Number of subjects: 24
Study 28034894 — intervention group
Group type: COMPARATOR
Intervention: 500 ml normal saline ingestion
Number of subjects: 24
Study 28034894 — intervention group
Group type: COMPARATOR
Intervention: 50 ml water ingestion
Number of subjects: 24
Study 26663687 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 25 mg
Number of subjects: 842
Study 26663687 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg
Number of subjects: 842
Study 26663687 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 100 mg
Number of subjects: 842
Study 26663687 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 842
Study 23819337 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically engineered biological agents (GEBAs), primarily rituximab (n = 66) and infliximab (n = 31)
Number of subjects: 107
Study 23819337 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically engineered biological agents (GEBAs)
Number of subjects: 107
Study 21694461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (after 8 weeks of low-dose vitamin D 1000 IU/day)
Number of subjects: 32
Study 21694461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insulin (60 IU qid for 48 hours after high-dose vitamin D)
Number of subjects: 32
Study 21694461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after high-dose vitamin D)
Number of subjects: 32
Study 21694461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after nasal insulin)
Number of subjects: 32
Study 18318569 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 0
Study 16153694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal alpha-interferon (50 x 10(6) IU weekly for 6 doses)
Number of subjects: 70
Study 16153694 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 70
Study 14502137 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgel
Number of subjects: 71
Study 14502137 — intervention group
Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 71
Study 10920049 — intervention group
Group type: EXPERIMENTAL
Intervention: random motion
Number of subjects: 9
Study 10920049 — intervention group
Group type: COMPARATOR
Intervention: static dots
Number of subjects: 9
Study 10920049 — intervention group
Group type: EXPERIMENTAL
Intervention: coherent motion (expansion or 3-D surface)
Number of subjects: 9
Study 10920049 — intervention group
Group type: EXPERIMENTAL
Intervention: coherent motion
Number of subjects: 9
Study 10920049 — intervention group
Group type: EXPERIMENTAL
Intervention: curved surface rotating in depth
Number of subjects: 9
Study 10920049 — intervention group
Group type: EXPERIMENTAL
Intervention: curved 3-D surfaces
Number of subjects: 9
Study 9377133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (1.4‐2.3 mg/kg/day)
Number of subjects: 33
Study 9377133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9377133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 33
Study 8266226 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms dose of hepatitis B vaccine
Number of subjects: 320
Study 8266226 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms dose of hepatitis B vaccine
Number of subjects: 320
Study 3512919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (12.5 ng/kg/min from heparinization until cardiopulmonary bypass, 25 ng/kg/min during bypass)
Number of subjects: 100
Study 3512919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 100
Study 3512919 — intervention group
Group type: COMPARATOR
Intervention: Buffer/diluent (Control)
Number of subjects: 100
Study 31114673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) and home exercise
Number of subjects: 241
Study 31114673 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise and home exercise
Number of subjects: 241
Study 31114673 — intervention group
Group type: COMPARATOR
Intervention: Home exercise alone
Number of subjects: 241
Study 31114673 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SMT, supervised rehabilitative exercise, home exercise)
Number of subjects: 241
Study 31114673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination groups (SMT + home exercise, supervised rehabilitative exercise + home exercise)
Number of subjects: 241
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (rehabilitation)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (enabling)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (review)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (assessment)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (supportive)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (activity to support therapy)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (overall therapy received)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (delivery personnel)
Number of subjects: 278
Study 29990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (session type)
Number of subjects: 278
Study 27485453 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 2 g/m(2) + G-CSF (arm A)
Number of subjects: 80
Study 27485453 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone (arm B)
Number of subjects: 80
Study 24862733 — intervention group
Group type: EXPERIMENTAL
Intervention: HVAD with ICD
Number of subjects: 41
Study 24862733 — intervention group
Group type: EXPERIMENTAL
Intervention: HVAD with history of VAs
Number of subjects: 41
Study 24862733 — intervention group
Group type: COMPARATOR
Intervention: HVAD without history of VAs
Number of subjects: 41